Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies

Hilma J van der Horst,Inger S Nijhof,Tuna Mutis,Martine E D Chamuleau,Hilma J. van der Horst,Inger S. Nijhof,Martine E. D. Chamuleau
DOI: https://doi.org/10.3390/cancers12103041
2020-10-19
Cancers
Abstract:Monoclonal antibody (mAb) therapy has rapidly changed the field of cancer therapy. In 1997, the CD20-targeting mAb rituximab was the first mAb to be approved by the U.S. Food and Drug Administration (FDA) for treatment of cancer. Within two decades, dozens of mAbs entered the clinic for treatment of several hematological cancers and solid tumors, and numerous more are under clinical investigation. The success of mAbs as cancer therapeutics lies in their ability to induce various cytotoxic machineries against specific targets. These cytotoxic machineries include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), which are all mediated via the fragment crystallizable (Fc) domain of mAbs. In this review article, we will outline the novel approaches of engineering these Fc domains of mAbs to enhance their Fc-effector function and thereby their anti-tumor potency, with specific focus to summarize their (pre-) clinical status for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL), B-cell non-Hodgkin lymphoma (B-NHL), and multiple myeloma (MM).
oncology
What problem does this paper attempt to address?
This paper aims to address the limitations of monoclonal antibody (mAb) therapy in the treatment of B - cell malignancies. Specifically, the authors focus on enhancing the Fc effector functions of mAbs through Fc region engineering, thereby improving their anti - tumor effects. The paper summarizes established and newly developed Fc - engineering strategies that aim to increase Fc effector functions and, in turn, enhance the anti - tumor potency of mAbs. In addition, as the number of Fc - engineered mAbs entering the (pre - clinical) clinical development stage is increasing, this article also provides a clear overview, describing specific types of Fc - engineering, their antigens and disease targets, and the current development stage, with particular attention to the treatment of chronic lymphocytic leukemia (CLL), B - cell non - Hodgkin lymphoma (B - NHL), and multiple myeloma (MM). The main contribution of the paper lies in systematically summarizing how Fc - engineering improves the therapeutic effects of mAbs by enhancing ADCC (antibody - dependent cell cytotoxicity), ADCP (antibody - dependent cell phagocytosis), and CDC (complement - dependent cell cytotoxicity), and providing details of these engineered mAbs in (pre - clinical) clinical development. This not only helps in understanding the mechanisms of Fc - engineering but also provides a valuable reference for future research and clinical applications.